Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LATS1 | O95835 | 2/20 | 0.32 |
| ▸ | LATS2 | Q9NRM7 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30639342 | 1.00 | LATS1 (0.32) | LATS1LATS2 | |
| SCHEMBL31571836 | 1.00 | LATS1 (0.32) | LATS1LATS2 | |
| SCHEMBL14734142 | 1.00 | LATS1 (0.32) | LATS1LATS2 | |
| SCHEMBL29576569 | 0.97 | LATS1 (0.32) | LATS1LATS2 | |
| SCHEMBL373792 | 0.95 | — | — | |
| SCHEMBL31491332 | 0.95 | — | — | |
| SCHEMBL30678865 | 0.94 | LATS1 (0.32) | LATS1LATS2 | |
| SCHEMBL30678840 | 0.94 | LATS1 (0.32) | LATS1LATS2 | |
| SCHEMBL30678848 | 0.94 | LATS1 (0.32) | LATS1LATS2 | |
| SCHEMBL31622416 | 0.90 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4678644-A1 | SUBSTITUTED DIHYDROTHIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | Shanghai Yidi Biotechnology Co., Ltd. (CN) | 2026-01-14 | — | — | EP | disclosed |
| US-20260008788-A1 | AZA-FUSED RING COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | SUZHOU ARK BIOPHARMACEUTICAL CO LTD (CN) | 2026-01-08 | — | — | US | disclosed |
| EP-4674852-A1 | PREPARATION METHOD FOR AND USE OF DIHYDROTHIENOPYRIMIDINE DERIVATIVE | Innovstone Therapeutics Limited (CN) | 2026-01-07 | — | — | EP | disclosed |
| US-20250270230-A1 | NOVEL SYNTHETIC STEPS FOR THE MANUFACTURING METHOD OF THE PDE4B-INHIBITOR 1-({(5R)-2-[4-(5-CHLOROPYRIMIDINE-2-YL)PIPERIDINE-1-YL]-5-OXIDO-6,7-DIHYDROTHIENO[3,2-D]PYRIMIDINE-4-YL}AMINO)CYCLOBUTYL]METHANOL | BOEHRINGER INGELHEIM INT (DE) | 2025-08-28 | — | — | US | disclosed |
| EP-4596554-A1 | AZA-FUSED RING COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | Suzhou Arkbiopharmaceutical Co., Ltd. (CN) | 2025-08-06 | — | — | EP | disclosed |
| WO-2025131986-A1 | NOVEL SYNTHETIC STEPS FOR THE MANUFACTURING METHOD OF THE PDE4B-INHIBITOR 1-({(5R)-2-[4-(5-CHLOROPYRIMIDINE-2-YL)PIPERIDINE-1-YL]-5-OXIDO-6,7-DIHYDROTHIENO[3,2-D]PYRIMIDINE-4-YL}AMINO)CYCLOBUTYL]METHANOL | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025124557-A1 | DEUTERATED HETEROCYCLIC COMPOUND ACTING AS PDE4B INHIBITOR AND USE THEREOF | 武汉人福创新药物研发中心有限公司 | 2025-06-19 | — | — | WO | disclosed |
| CN-120157682-A | Deuterated heterocyclic compounds as PDE4B inhibitors and uses thereof | 武汉人福创新药物研发中心有限公司 | 2025-06-17 | — | — | CN | disclosed |
| WO-2025067168-A1 | AZA FUSED RING COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 苏州爱科百发生物医药技术有限公司 | 2025-04-03 | — | — | WO | disclosed |
| CN-119698422-A | Aza condensed ring compound, preparation method and medical application thereof | 苏州爱科百发生物医药技术有限公司 | 2025-03-25 | — | — | CN | disclosed |
| WO-2025038987-A2 | PDE4 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | KATALYTIC THERAPEUTICS, INC. (US) | 2025-02-20 | — | — | WO | disclosed |
| CN-118871444-A | Preparation method and application of dihydro-thienopyrimidine derivative | 上海翊石医药科技有限公司 | 2024-10-29 | — | — | CN | disclosed |
| WO-2024179493-A1 | PREPARATION METHOD FOR AND USE OF DIHYDROTHIENOPYRIMIDINE DERIVATIVE | 上海翊石医药科技有限公司 | 2024-09-06 | — | — | WO | disclosed |
| CN-118146236-A | Substituted dihydrothienoazaheteroaryl derivatives, methods of preparation and use of prodrugs thereof | 上海翊石医药科技有限公司 | 2024-06-07 | — | — | CN | disclosed |
| WO-2023241684-A1 | PDE4B INHIBITOR | 武汉人福创新药物研发中心有限公司 | 2023-12-21 | — | — | WO | disclosed |
| CN-117247395-A | PDE4B inhibitors | 武汉人福创新药物研发中心有限公司 | 2023-12-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270230-A1 | NOVEL SYNTHETIC STEPS FOR THE MANUFACTURING METHOD OF THE PDE4B-INHIBITOR 1-({(5R)-2-[4-(5-CHLOROPYRIMIDINE-2-YL)PIPERIDINE-1-YL]-5-OXIDO-6,7-DIHYDROTHIENO[3,2-D]PYRIMIDINE-4-YL}AMINO)CYCLOBUTYL]METHANOL | PDE4B, PDE3B, PDE5A | LATS1 3710/4885LATS2 3270/4885 |
| US-20260008788-A1 | AZA-FUSED RING COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | PDE4B, PDE4A, CYP4A11 | LATS1 3539/4885LATS2 3994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.